Why the study?
Although overshadowed by CRISPR-based genome editing, RNA editing has seen rapid development with improvements in efficiency and precision, prompting a summary of core components, editing types, delivery methods, and future directions.
Provides a comprehensive overview of RNA base editing technologies, their delivery methods, and therapeutic potential for diseases caused by nonsense mutations.
RNA base editing advances may enable precise mutation correction; leaves open clinical translation pending prospective validation.
RNA base editing, which enables RNA base modification through effector proteins guided by targeting systems, is a powerful technology to correct disease-associated point mutations. Although overshadowed by CRISPR-based genome editing, RNA editing has seen rapid development in recent years, with significant improvements in efficiency and precision. In this review, we summarize the core components of RNA base editing systems (RNA-targeting systems and effector proteins) and describe major RNA editing types, including A-to-I, C-to-U, A-to-m 6 A/m 6 A-to-A, and U-to-Ψ base editors, along with their research progress. In addition, we systematically summarize the delivery methods of the developed RNA editors and their initial exploration in treating diseases caused by nonsense mutations. Finally, combining the current development status of the RNA editing related field, we reflect on the problems encountered in the current development of the RNA editing field and offer our own insights on the future development direction.
No takes yet. Share an insight, caveat, or question.
Xiaocheng Weng (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: